item management s discussion and analysis of financial condition and results of operations the results for the three years ended december   and have been restated from prior periods to reflect the merger of shire pharmaceuticals group plc and roberts pharmaceutical corporation as if the merger had occurred on january  the following discussion should be read in conjunction with the company s consolidated financial statements and related notes appearing elsewhere in this report 
results of operations years ended december  and overview on december   shire and roberts merged in a tax free exchange of shares 
shire exchanged adss for each common share of roberts 
this transaction was accounted for as a pooling of interests 
merger transaction expenses and merger related restructuring costs totaled million and are reflected in shire s accounts 
for the year ended december   total revenue increased by to million  compared to million in fiscal this increase was primarily the result of an increase in product sales 
product sales in the us continue to represent a significant percentage of worldwide sales  increasing to in from in the company manages and controls the business on geographic lines 
the three reportable segments are the united states  europe and the rest of the world 
additional information regarding segments is provided in note to the consolidated financial statements 
product sales product sales by segment change change m m m united states europe rest of world total product sales for the year ended december   total product sales increased by to million  compared to million in the prior year 
of the company s total product sales  related to adderall and dextrostat  the company s products marketed in the us for the treatment of adhd 
on a combined basis  these products increased their share of the total us adhd prescriptions written from in december to in december other significant contributors to the increase in product sales in were the us marketed products pentasa  carbatrol and agrylin 
the company acquired pentasa  licensed for the treatment of ulcerative colitis  in the second quarter of  and recorded sales of million in compared to million in carbatrol increased its share of total us extended release carbamazepine prescriptions written to at december  from in december and agrylin sales grew over to million in cost of sales for the year ended december  cost of sales amounted to of product sales as compared to in the decrease in cost of sales percentage and corresponding increase in gross margin is attributable to an improved product mix due to the faster growth of products with a higher gross margin 
additionally  the company acquired all rights to agrylin including the ending of royalty obligations from bristol myers squibb  which enhanced the gross margin of this product 
costs and expenses in the company recorded charges totaling million pre tax for asset impairments million  merger related transaction expenses million  restructuring million  loss on product dispositions million and other charges million 
these charges are disclosed separately within operating expenses in the statement of income 
the company recorded an impairment charge of million to adjust intangible asset values  primarily product rights  to their estimated fair value 
these charges are consistent with the company s accounting policy to review periodically the carrying value of the intangibles and evaluate whether there has been any impairment in the carrying value of those intangibles as compared with estimated undiscounted future cash flow relating to those intangibles 
other asset impairments are the write off of inventory held for research and development work and duplicate equipment million  adjustments to the carrying value of the ribogene investment to its estimated realizable value at december  million  and write down of notes receivable to their estimated realizable value million 
the components of the restructuring charge are as follows millions employee termination costs property in december  the decision was made to close the roberts office facility in eatontown  new jersey and consolidate the sales and marketing operations into the existing shire facility in florence  kentucky and to transfer the research development activities to shire s facility in rockville  maryland 
similarly  roberts sales and marketing operation in the uk was combined with shire s established operation in andover  hampshire 
as a result of the restructuring and elimination of duplicate facilities  employees will be terminated 
these positions were mainly based in the us working in the sales and marketing  research and development and administrative functions 
all employees were notified of their termination prior to december  included in the employee termination costs is approximately million related to pension contributions  which was paid prior to the year end 
the company anticipates all activities associated with this restructuring to be substantially complete at the end of with the remaining cash expenditures expected in this period 
the termination costs consist of payments for severance  medical and other benefits  outplacement counseling  pension contributions and excise taxes 
shire has commenced negotiations with potential purchasers of the property at eatontown  which has been written down to its estimated fair value 
the company anticipates realizing annual savings resulting from the merger of approximately million 
research and development research and development expenditure increased from million in to million in  representing an overall increase of 
this increase reflects the significant portion of development projects at phase ii or later where development costs tend to be higher 
selling  general and administrative expenses selling  general and administrative expenses increased million from million in to million in fiscal  primarily due to an increase in size of the us sales force and higher levels of marketing expenditure 
as a percentage of total revenues  selling  general and administrative expenses were constant at approximately in and a significant component of selling  general and administrative expenses is amortization  which increased from million in to million in  due to the addition of the pentasa and agrylin product rights 
interest income and expense in the year ended december  the company received interest income of million compared with million in interest expense increased from million in to million in as a result of a full year s interest expense from the financing of the pentasa acquisition 
income taxes for the year ended december   income taxes increased million from million to million 
the company s effective tax rate in before merger related transaction expenses  restructuring costs and asset impairments was 
the company has recorded net deferred tax assets of approximately million 
realization is dependent upon generating sufficient taxable income to utilize such assets 
although realization on these tax assets is not assured  management believes it is more likely than not that the deferred tax assets will be realized 
years ended december  and total revenues for the year ended december   total revenue increased by to million  compared to million in fiscal this increase was primarily the result of an increase in product sales 
product sales for the year ended december   total product sales increased by to million  compared to million in the prior year 
the fiscal year ended december  included the results of shire richwood  inc sri for days whereas in the results are included for a full year 
sri contributed million in compared to million in of sri s total product sales  related to adderall and dextrostat  the company s products for the treatment of adhd in the us on a combined basis  these products increased their share of the total us adhd prescriptions written from in august  the month of acquisition  to in december and to in december carbatrol  an extended release formulation of carbamazepine  was launched in the us in june carbamazepine is used as a first line treatment for epilepsy  a condition that affects approximately million people in the us since its launch  carbatrol has become one of shire s largest products with sales of million in a significant contributor to the increase in product sales in the us  acquired by the company in the second quarter of  was pentasa with sales of million 
increased sales of the us marketed products  agrylin and proamatine contributed million and million to the increase over sales levels respectively 
cost of sales for the year ended december  cost of sales amounted to of product sales as compared to in this decrease in cost of sales percentage and corresponding increase in gross margin is attributable primarily to the addition of pentasa and its higher gross margin to the product mix  and to the inclusion of the comparatively higher gross margin adhd products for a full year 
research and development research and development expenditure increased from million in to million in  representing an overall increase of 
in  shire in licensed from neurosearch a s a series of ampa antagonists for disorders of the central nervous system 
selling  general and administrative expenses selling  general and administrative expenses increased million from million in to million in fiscal a significant contributor to the increase was a rise in amortization expense of million  due to the addition of the pentasa product rights full years charge on the capitalized goodwill resulting from the acquisitions of shire laboratories and shire richwood 
as a percentage of total revenues  selling  general and administrative expenses decreased from in to in fiscal other charges as a result of the acquisition of shire laboratories in march  shire incurred a charge of million  representing the acquisition of in process research and development 
interest income and expense in the year ended december  the company received interest income of million compared with million in interest expense increased from million in to million in as a result of interest costs from the financing of the pentasa acquisition 
income taxes for the year ended december   income taxes increased million from million to million 
the company s effective tax rate in was 
the company has recorded net deferred tax assets of approximately million 
realization is dependent upon generating sufficient taxable income to utilize such assets 
although realization on these tax assets is not assured  management believes it is more likely than not that the deferred tax assets will be realized 
liquidity and capital resources the company has financed its operations since inception through private and public offerings of equity securities  the issuance of loan notes  collaborative licensing and development fees  product sales and investment income 
the company s funding requirements depend on a number of factors  including the company s product development programs  business and product acquisitions  the level of resources required for the expansion of marketing capabilities as the product base expands  increased investment in accounts receivable and inventory which may arise as sales levels increase  competitive and technological developments  the timing and cost of obtaining required regulatory approvals for new products  and the continuing revenues generated from sales of its key products 
as of december   and the company had cash  cash equivalents and marketable securities of million  million and million  respectively which consisted of immediately available money market fund balances and investment grade securities 
debt in  the company acquired the product rights to pentasa 
the majority of the purchase price was financed through a credit agreement between roberts  dlj capital funding and various other lenders 
under this credit agreement  the merger of shire and roberts constituted a change of control  which would trigger the acceleration of the repayment of the principal amounts outstanding 
on november   roberts  shire s us subsidiaries and shire entered into an agreement with dlj to replace the existing credit agreement with a million credit facility consisting of a million five year revolving credit facility and a million five year term loan facility 
in connection with the credit facility  the company is subject to certain affirmative and negative covenants and maintenance tests that require the company to maintain a minimum net worth  a specified leverage ratio and a specific coverage ratio 
at december  the company satisfied the aforementioned covenants and maintenance tests 
capital expenditure capital expenditures in of approximately million were principally for the upgrade and expansion of sales and administration functions 
expenditure in of approximately million primarily relates to an upgrade of the manufacturing facility in canada and significant investments in new computer hardware and software 
business combinations and divestitures during october and november the company acquired the european sales and marketing subsidiaries from fuisz technologies ltd 
the operations located in france  germany and italy were acquired for approximately million in cash 
a substantial portion of the purchase price was allocated to intangible assets  which are amortized over years 
on december  shire pharmaceuticals group plc  and roberts pharmaceutical corporation merged in a tax free exchange of shares 
this transaction was accounted for as a pooling of interests 
shire exchanged adss for each common share of roberts 
merger transaction expenses and merger related restructuring costs totaled million 
these charges are disclosed separately in operating expenses 
on january  shire disposed of its indianapolis manufacturing plant for a net consideration after expenses of million including a loan note of million 
the net gain of million is included in results of operations 
during november  the company sold the product tigan for million 
the company incurred a loss on disposal of million  which is included within the results of operations 
other commitments information regarding other commitments is disclosed in note to the consolidated financial statements 
foreign currency fluctuations the group s parent company and a number of subsidiary operations are located outside the united states 
as such  the consolidated financial results are subject to fluctuations in exchange rates  particularly those between the us dollar and british pound 
the accumulated foreign currency translation differences are reported within accumulated other comprehensive income 
concentration of credit risk financial instruments that potentially expose the company to concentrations of credit risk consist primarily of short term cash investments and trade accounts receivable 
as revenues are mainly derived from agreements with major pharmaceutical companies and relationships with drug distributors  and such clients typically have significant cash resources  any credit risk associated with these transactions is considered minimal 
the company operates credit evaluation procedures 
excess cash is invested in short term money market instruments  including bank and building society term deposits and commercial paper from a variety of companies with strong credit ratings 
these investments typically bear minimal risk 
inflation although at reduced levels in recent years  inflation continues to apply upward pressure on the cost of goods and services used by the company 
however  management believes that the net effect of inflation on the company s operations has been minimal during the past three years 
year the year yk issue results from the inability of some computer programs to identify the year properly  potentially leading to errors or systems failures 
the company did not incur any significant problems relating to the yk issue and does not expect to incur significant expenses to remediate minor operating issues 
euro conversion on january   the european economic and monetary union the emu introduced the euro as the official currency of the participating member countries 
on that date  the currency exchange rates of the participating countries were fixed against the euro 
there is a three year transition to the euro  and at the end of the currency will come into circulation and national currencies will be withdrawn by july the uk did not participate in the emu at the commencement of the third stage on january  and it is uncertain whether or on what terms the uk would be permitted to join at a later date 
there can be no prediction as to whether the uk will participate in the emu or as to the rate at which the pound sterling would be converted into the euro 
furthermore  there can be no prediction as to the likely impact on the us dollar sterling exchange rate of a decision by the uk to participate in the emu 
it is anticipated that the pricing of goods and services will be more transparent through the use of a single currency within the participating member states 
competition is likely to increase with the greater price transparency and removal of exchange rate risk 
in the longer term more general price convergence is likely  assuming the emu leads to greater harmonization of healthcare policies across the participating member states 
shire has sales and marketing operations in france  germany and italy and therefore there may be some impact on the company s business and competitive position as a result of the increased price transparency 
the company has reviewed its financial and operating systems and is satisfied that the introduction of the euro will not cause any disruption to the business  and that the systems are in place to receive and make payments in euros 
shire will continue to monitor the uk s stance in relation to participation in the euro and assess the impact of any significant changes in policy 
item a quantitative and qualitative disclosures about market risk shire s principal treasury operations are managed by the group s treasury function based in the uk in accordance with the group s treasury policies and procedures which are approved by shire s board 
as a matter of policy  shire does not undertake speculative transactions which would increase its currency or interest rate exposure 
the company is subject to market risk exposure in the following areas interest rate market risk the company has cash and cash equivalents on which interest income is earned at variable rates 
the financing and cash management requirements of the operating subsidiaries are transacted within the group s treasury function  where appropriate  in order to improve the return on liquid assets  manage any currency exposure on non us dollar denominated deposits and maintain internal controls 
the company also has a million credit facility composed of a million five year revolving credit facility including a million letter of credit facility and a million five year term loan facility 
the applicable interest rate on the credit facility ranges between and over the prime rate of dlj capital funding  inc or the federal funds rate plus or between and over the london interbank overnight rate  in each case depending on shire s credit rating 
the facility is secured by all material property owned by shire and its subsidiaries and the capital stock of shire s subsidiaries 
if shire s credit rating reaches specified levels  the facility will not be secured 
the facility contains customary covenants and additional maintenance tests that require shire to maintain a minimum net worth  a specified leverage ratio and a specified coverage ratio 
the company has no amounts due in respect of debt denoted in foreign currencies 
foreign exchange market risk the group s parent company and a number of subsidiary operations are located outside the united states 
as such  the consolidated financial results are subject to fluctuations in exchange rates  particularly between the british pound and canadian dollar against the us dollar 
the financial statements of foreign entities are translated using the accounting policies described in note of the notes to the consolidated financial statements 
the exposure to foreign exchange market risk is managed by the group s treasury function  using forecasts provided by the operating units 
derivative instruments in the form of average rate options are used to hedge shire s currency exposures 
the premium paid for the options is amortized over the hedging period 
there were no derivatives outstanding at december  or 
